Motif Neurotech selected by UK ARIA for multimillion dollar award to develop psychiatric BCI
Summary
Motif Neurotech was selected by the UK's Advanced Research and Invention Agency (ARIA) for a multimillion dollar award to support development of their therapeutic BCI technology for cognitive and psychiatric conditions — in addition to the RESONATE FDA IDE approval for treatment-resistant depression in the US. ARIA's investment represents the UK government's first significant funding commitment to implantable therapeutic BCI for mental health, signaling UK intent to build psychiatric BCI expertise domestically.
Why it matters
ARIA's selection of Motif Neurotech creates a transatlantic dimension to their development program — US clinical trials via RESONATE alongside UK research investment via ARIA. This dual-country approach de-risks Motif's regulatory strategy and could accelerate the international evidence base for wireless psychiatric brain stimulation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial